Companies
BioMar Group
the world's #3 aquafeed producer by volume; 2025 feed volume 1.56M t (+13%, shrimp +31%) on revenue DKK 16.53 bn ($2.42 bn) and ROIC 23.6%; IPO on Nasdaq Copenhagen on 28 May 2026 at DKK 108/share (market cap DKK 10.85 bn), the sector's flagship 2026 capital-markets event.
- Country
- Denmark
- Ticker
- CPH:BIOMAR
Nasdaq CPH-listed (May 2026)
Ecuador+China capacity expansion
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| aquaculture-seafood | ✓ | ✓ | ✓ | ✓ |
| livestock-aqua | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaefsamoa-china
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Founded | Founded as Dansk Ørredfoder in 1962 (1962-01-01) | bitscale.ai · investors.biomar.com |
| Headquarters | Aarhus, Denmark (2026-05-01) | investors.biomar.com · biomar.com |
| Capacity | Approximately 2.0 million tonnes seasonalised production capacity (2026-05-01) | bitscale.ai · investors.biomar.com |
| Production site | 16 feed production facilities in Norway, Chile, Denmark, Scotland, Spain, France, Vietnam, Greece, Turkey, China, Ecuador, Australia, and Costa Rica (2026-05-01) | investors.biomar.com · seafood.media · biomar.com |
| Headcount | 1,775 employees on average (H1 2026) (2026-06-30) | biomar.com |
| Revenue | DKK 16.53 billion (FY 2025) (2025-12-31) | investors.biomar.com · biomar.com |
| Funding | Initial Public Offering (IPO) on Nasdaq Copenhagen intended/launched May 2026 (2026-05-19) | investors.biomar.com |
| Certification | ISO 9001, BAP, GLOBALG.A.P., ASC, and other market-specific standards across global facilities (2026-05-01) | biomar.com |
| Regulatory approval | IPO Offering Circular approved by the Danish Financial Supervisory Authority (2026-05-19) | investors.biomar.com |
Independent sources: bitscale.ai · seafood.media
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Aquaculture & fish farming | livestock-aqua | Medium | → |
| Microalgae (seafood/feed) | aquaculture-seafood | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.